31 results about "Treated patient" patented technology

The present invention is in the field of ocular disease therapy. In particular, the invention relates to a composition comprising pimecrolimus for use in the topical treatment of moderate to severe blepharitis, in particular in a patient group comprising subjects with a clinical diagnosis of moderate to severe blepharitis, wherein the subjects to be treated have signs and symptoms of moderate to severe blepharitis characterised by swelling of the eyelid margin, ocular debris and ocular discomfort. In particular, the present invention relates to an ophthalmic composition that shows a high patient acceptance and a clinically meaningful improvement in the signs and symptoms of treated patients.

A system and method for determining patient hospitalization risk and treating patients is disclosed. The system and method may include extracting patient data from one or more databases corresponding to a pool of patients having end stage renal disease; using a predictive model with the extracted patient data to generate, for each of the patients, a respective expected probability for hospitalization within a predetermined time period; identifying a subset of patients having respective expected probabilities that are higher than other patients in the pool of patients; identifying, for each patient, at least one factor from the patient data that increased the expected probability of hospitalization; and based on the identified factors, determining and executing clinical interventions to lower the probability of hospitalization within the subset of the pool of patients.

A patient support apparatus for use in treating patients with behavioral health indicia, including a base supporting wheels for movement along a floor surface, a litter for supporting a patient, and a lift mechanism to move the litter relative to the base between a lowered position and a raised position. A skirt barrier having a bottom edge defining a periphery is operatively attached to the litter for concurrent movement with the litter between an exposed configuration and a shield configuration. The exposed configuration corresponds to the raised position and is defined with the bottom edge spaced vertically above the base. The shield configuration corresponds to the lowered position and is defined with the bottom edge arranged adjacent to the floor surface and with the periphery extending around the base to at least partially limit external access to the base.

This application generally relates to an transcatheter anti-reflux venous valve endoprosthesis system, including a replacement valve, a valve support frame, crimping system, and delivery system to treat patients with chronic venous insufficiency, and method for using such a system.

Provided herein are methods for determining a subtype of a small cell lung cancer in a patient based on the express status of ASCL1, NEUROD1, and POU2F3, which are expressed in a mutually exclusive fashion. The subtype of the cancer can be used to determine the sensitivity of the cancer to certain anti-cancer therapies. As such, also provided are methods of treating patients having small cell lung cancer based on the subtyping results.

The present invention relates to methods for treating patients with cancer, including patients with hematological malignancy, wherein the method comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are as defined herein.

This utility model discloses a medical split-type underwear, comprising a medical underwear with an opening through which a split-type block is movably connected. A loop is fixedly connected to the medical underwear. A bell-shaped buckle shell is movably connected to the side of the medical underwear. The loop has symmetrical first tightening openings and second tightening openings on its side. An elastic cord is movably connected inside the loop. A locking shaft is movably connected inside the bell-shaped buckle shell. A Z-shaped plastic elastic block is movably connected inside the bell-shaped buckle shell. Symmetrical first Velcro fasteners are fixedly connected inside the medical underwear. Symmetrical second Velcro fasteners are fixedly connected to the split-type block. This structure allows for quick splitting, facilitating medical personnel in examining and treating patients, meeting different nursing needs, improving flexibility and hygiene, and ensuring wearing comfort.

Provided are materials and methods for treating patients with hemoglobinopathies, either ex vivo or in vivo. Also provided are materials and methods for deleting and / or mutating a portion of a human beta globin locus on chromosome 11 and one or more of: a BCL11 A gene on chromosome 2, and a DNA sequence that encodes a transcriptional control region of the BCL11 A gene on chromosome 2, in a human cell by genome editing and thereby increasing the production of fetal hemoglobin (HbF) in the genome-edited human cells.

A method for treating patients with NOTCH3 mutations using a rho kinase inhibitor has been disclosed. Abnormal NOTCH3 signaling is a pathological factor in cerebral small vessel diseases, including CADASIL. A preferred embodiment relates to treating patients orally with the rho kinase inhibitor fasudil or its active metabolite hydroxyfasudil.

The disclosure relates to peptide conjugates specific for Epithelial cell adhesion molecule (EpCAM) and the use thereof to detect and treat epithelial cell-derived cancers such as intrahepatic cholangiocarcinoma (ICC), hepatocellular carcinoma (HCC), breast cancer, colon cancer and basal cell carcinoma of the skin. The disclosure also relates to methods to monitor the therapeutic response of treated patients by detecting expression of EpCAM.

Provided are an INHBE gene-targeted double-stranded oligonucleotide, a conjugate, and a composition, which relate to the technical field of nucleic acid drugs. The double-stranded oligonucleotide comprises a sense strand and an antisense strand. The antisense strand is complementary or substantially complementary to the sense strand; the sense strand comprises a nucleotide sequence identical or substantially identical to at least 15 contiguous nucleotides in a sequence of SEQ ID NO: 309, and said substantially identical means that there is no more than three nucleotide differences between the sense strand and the at least 15 contiguous nucleotides in the sequence of SEQ ID NO: 309. The double-stranded oligonucleotide can effectively inhibit the INHBE gene and treat patients suffering from metabolic diseases or metabolic syndrome and related diseases such as diabetes, hypertension and cardiovascular diseases.

We disclose here the nano-enabled delivery of highly potent 5-hydroxymethyl furfural (5-HMF) to sickled blood cells in patients. 5-HMF, a superior antisickling agent, has been formulated to address the limitations of existing treatment modalities arising from disfavorable pharmacokinetics of the drug compound. Specifically, two complementary 5-HMF prodrugs are integrated as a ‘protected’ biocompatible composite nanoparticle designed to readily fuse with RBCs and be amenable to transdermal delivery (5-HMF-grafted-phospholipid layered over a sucrose-derived graphitic carbon dot core). These RBC-targeted, protected, biocompatible, self-assembled 5-HMF prodrug nanoparticles for sickle cell disease are the first in class technology for offering a treatment for sickle cell disease which has improved potency, targeted payload delivery, and extended release with the red blood cells with enhanced pharmacodynamic effect in a treated patient.

Devices, systems, and methods are provided for recognizing, diagnosing, mapping, sensing, monitoring and / or treating selected areas within a patient's body. The systems, devices and methods may be used to map, detect and / or quantify images and / or physiological parameters collected from the patient. One such system comprises an optical imaging device, such as an endoscope, and a processor coupled to the imaging device. The processor includes a software application configured to recognize the images captured by the optical imaging device and determine if the tissue contains a medical condition and may include an artificial neural network configured to develop at least one set of computer-executable rules useable to recognize the medical condition in the captured tissue images. The systems, devices and methods provided herein allow for a more objective and comprehensive inspection of the targeted areas within a patient so as to improve the diagnosis and ultimate treatment of patients.

Provided herein are methods of treating a subject with a complement pathway inhibitor based on the subject's complement pathway activity. Also provided herein are methods of stratifying a subject into three groups based on the subject's complement pathway activity: hyperactive, homeostatic, and hypoactive, and administering an effective treatment (e.g., complement pathway inhibitors).

Provided herein are methods and systems for treating patients with a TEAD inhibitor, selecting patients suitable for treatment, and measuring efficacy of treatment with same.

The present invention relates to methods of treating patients with neutropenia, such as severe chronic neutropenia, or a related disorder, in which a CXCR4 inhibitor, or a pharmaceutically acceptable salt thereof, is administered to such patients. In some cases, the methods have the advantage of reducing or eliminating side-effects from co-administered agents.

This technology aims to provide a novel type of drug for treating patients suffering from cancer. [Solution] Specifically, this technology provides a polypeptide comprising at least four immunoglobulin monovariable domains (ISVDs), characterized in that one ISVD binds to the TCR and at least two ISVDs bind to GPC3. This technology also provides nucleic acids, vectors, and compositions.

The present disclosure relates to liquid formulations containing acetaminophen and ibuprofen. In particular, the present disclosure relates to liquid formulations comprising acetaminophen, ibuprofen, and a sulfite compound. Such liquid formulations are suitable for parenteral (e.g., intravenous) administration. The present disclosure also relates to terminally-sterilized acetaminophen / ibuprofen liquid formulations. The present disclosure also relates to methods of treating patients by administration of such formulations and polymeric infusion containers, including flexible polymeric infusion containers, containing such formulations.

The present invention addresses the problem of providing a novel therapeutic agent for treating patients with anti NMDAR encephalitis. Patients with an anti NMDAR encephalitis have a pathogenic anti-human NR1 antibody that induces internalization of NMDAR on cell surface. As a result, NMDAR function is weakened in the patients' brain. The present inventors found that the one-armed anti-human NR1 antibody according to the present invention binds to NR1 competitively with the pathogenic anti-human NR1 antibody and inhibits the internalization of NMDAR by the pathogenic anti-human NR1 antibody to thereby exhibit therapeutic effect on anti NMDAR encephalitis. Accordingly, the present invention provides the a one-armed anti-human NR1 antibody, a polynucleotide encoding the antibody, an expression vector containing the polynucleotide, a host cell transformed by the expression vector, a method for producing the antibody, a pharmaceutical composition comprising the antibody, a use of the antibody in the manufacture of the pharmaceutical composition, and a method for treating anti NMDAR encephalitis using the antibody.

A pharmaceutical composition, comprising panobinostat and tazemetostat. Combination of tazemetostat which is an EZH2 inhibitor with panobinostat, pembrolizumab and ipilimumab is clinically used for treating patients suffering from later-stage diffuse midline glioma, H3K27-altered, accompanied with leptomeningeal / pia mater spinalis spread, and patients suffering from primary, relapsing and progressing diffuse midline glioma, H3K27-altered. The pharmaceutical composition has remarkable curative effects, can obviously inhibit tumor growth, reduce the tumor volume, improve the life quality for patients, and prolong the survival time of patients.

The present disclosure relates to methods of treating patients having liver cancer by performing a genome-targeting technique. It is based, at least in part, on the discovery that a genome editing technique that specifically targets genomic mutations can induce cell death in a cancer cell, e.g., a hepatocellular cancer cell, having the genomic gene. The present disclosure provides methods for treating cancer patients that include performing a genome editing technique targeting a genomic mutation present within one or more cells of a subject to produce an anti-cancer effect.

The present disclosure relates to liquid formulations containing acetaminophen and ibuprofen. In particular, the present disclosure relates to liquid formulations comprising acetaminophen, ibuprofen, and a sulfite compound. Such liquid formulations are suitable for parenteral (e.g., intravenous) administration. The present disclosure also relates to terminally-sterilized acetaminophen / ibuprofen liquid formulations. The present disclosure also relates to methods of treating patients by administration of such formulations and polymeric infusion containers, including flexible polymeric infusion containers, containing such formulations.

Conventional cancer treatments are often ineffective, and therefore, there remains a need to develop more targeted and potent therapies to treat HCC. Antibody-drug conjugates (ADCs), which include antibodies that target GPC3 and are conjugated to cytotoxic drugs via a chemical linker, provide targeted therapies for treating patients with HCC tumors that express GPC3. [Solution] This disclosure provides GPC3 antibody-drug conjugates (ADCs), and includes compositions and methods for using such ADCs.

1. Name of this design product: Passenger car interior (Dental protection vehicle interior). 2. Purpose of this design: A vehicle used for receiving and treating patients with dental diseases and for preventing and treating dental diseases (the interior of the bus contains dental disease prevention and treatment equipment). 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: 3D view 1. 5. The bottom of the product is uncommon, so the bottom view is omitted.

The present disclosure provides a foam vascular plug, comprising a first part and a second part connected to each other, and the cross-sectional area of the first part in a cross section perpendicular to the axial direction is greater than the cross-sectional area of the second part in a cross section perpendicular to the axial direction, wherein the first part is made of a deformable foam material, and the second part is made of a deformable foam material. The foam vascular plug in an embodiment of the present disclosure, by setting the first part and the second part with different cross-sectional areas, the first part with a larger cross-sectional area can block the blood vessels at a specific position when it is not compressed, and the second part with a smaller cross-sectional area can facilitate the movement of the foam vascular plug in the blood vessels when it is compressed. Therefore, the foam vascular plug of the present disclosure has strong sheathability, high expansion rate and short expansion time, which helps to treat patients.

This application relates to the fields of artificial intelligence and traditional Chinese medicine (TCM) healthcare technology, and provides a method for synchronously updating a TCM model and application system based on a data flywheel. The method includes: acquiring first data; the first data being collected clinical data; training a first diagnostic and treatment model based on the first data to obtain a trained second diagnostic and treatment model; inputting the first patient's first symptom information into the second diagnostic and treatment model to obtain the first diagnostic and treatment information corresponding to the first patient; acquiring first feedback data; the first feedback data including first correction information corresponding to the first diagnostic and treatment information and actual therapeutic effect information after treating the first patient using the first correction information; training the second diagnostic and treatment model based on the first feedback data to obtain a trained third diagnostic and treatment model; and using the third diagnostic and treatment model to treat patients. This method enables the medical diagnostic and treatment model to dynamically adapt to new needs and scenarios arising in clinical practice, improving the diagnostic accuracy and practicality of the medical diagnostic and treatment model.

The application discloses non-coding RNA tRF-18-EY0VWUD2 as a biomarker for predicting breast cancer CDK4 / 6 inhibitor drug resistance. The application firstly finds that tRNA-derived small RNA, i.e., tRF-18-EY0VWUD2, can be used as a biomarker for predicting breast cancer CDK4 / 6 inhibitor drug resistance. Research results show that tRF-18-EY0VWUD2 is significantly highly expressed in CDK4 / 6 inhibitor drug resistance cell lines and patient serum, the PFS of patients with high expression of tRF-18-EY0VWUD2 is significantly poorer than that of patients with low expression of tRF-18-EY0VWUD2, and tRF-18-EY0VWUD2 is an independent prognostic factor for the curative effect of CDK4 / 6 inhibitor treated patients.

A patient interface for treating patients with respiratory diseases includes an RPT device including an electric blower configured to produce pressurized breathable air; a user interface structure configured to engage with the patient's face and at least partially form a plenum chamber configured to receive pressurized breathable air; a head-mounted interface configured to substantially cover the patient's eyes; a flow generator casing at least partially surrounding the head-mounted interface and the electric blower and connected to the plenum chamber, the flow generator casing including at least one air opening for receiving ambient air to be delivered to the RPT device; and a positioning and stabilizing structure configured to maintain the user interface structure in a therapeutically effective position.

In mass casualty (MASCAL) or similar events, combat medics often omit using body substance isolation (BSI) equipment, specifically disposable gloves, as donning gloves takes critical time away from treating patients. A multilayer glove loader and methodology of use that allows users to quickly put on multiple layers of gloves simultaneously addresses these concerns.